Jim Cramer Backs Ingredion as Ingredient Powerhouse After Tate & Lyle Deal
1h ago|4 min readStandard
Fazen Markets Editorial Desk
Collective editorial team · methodology
ingrediontate-lyle
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD 24/5 on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. Vortex HFT is informational software — not investment advice. Past performance does not guarantee future results.
CNBC commentator Jim Cramer endorsed Ingredion Incorporated's strategic positioning following its agreement to acquire Tate & Lyle PLC’s specialty food ingredients businesses for $1.3 billion. The transaction, announced on June 20, 2026, is structured as a cash-and-stock deal and is projected to be accretive to Ingredion's adjusted earnings per share within the first full year post-closure. Cramer's analysis on 'Mad Money' highlighted the deal's potential to transform Ingredion into a dominant supplier of value-added ingredient solutions.
The global food ingredients sector is consolidating as companies seek scale to meet rising demand for plant-based and reduced-sugar products. This acquisition echoes Kerry Group's $1.0 billion purchase of Niacet in 2025, which expanded its preservation technology portfolio. Ingredion's move accelerates a multi-year pivot away from commoditized sweeteners like high-fructose corn syrup and toward higher-margin specialty ingredients.
Persistent inflation in agricultural raw materials has pressured margins for pure-play commodity processors. The deal allows Ingredion to diversify its revenue base with Tate & Lyle's stable, contract-based specialty sales. Regulatory shifts, including sugar taxes in over 40 countries, continue to drive demand for alternative sweeteners, a core strength of the combined entity.
The transaction's timing coincides with a period of relative stability in capital markets, enabling favorable financing conditions. Ingredion will fund the purchase with a combination of cash on hand and new debt issuance. Shareholder approvals are pending, with regulatory clearances expected from antitrust bodies in the United States and European Union.
The $1.3 billion acquisition price represents a significant premium to the acquired assets' book value. Tate & Lyle's specialty ingredients division reported approximately $700 million in revenue for fiscal 2025. Ingredion's pro forma revenue will approach $9.5 billion annually, narrowing the gap with industry leader International Flavors & Fragrances Inc. (IFF).
Ingredion estimates annual pre-tax cost synergies of $100 million within three years of closing. The company projects the deal will be accretive to adjusted EPS by $0.75 to $1.00 in the first full year. Ingredion's stock (INGR) closed at $118.50 on June 19, up 12% year-to-date versus the S&P 500's 8% gain.
| Metric | Ingredion Standalone | Pro Forma Combined Entity |
|---|---|---|
| Estimated Annual Revenue | ~$8.8B | ~$9.5B |
| Specialty Sales Mix | ~35% | ~45% |
| Geographic Revenue (ex-N.A.) | ~40% | ~50% |
The combined entity will hold a leading market share in texturants and specialty sweeteners in North America and Europe. Ingredion's net debt to adjusted EBITDA ratio is expected to temporarily rise above 3.0x before deleveraging post-integration.
The merger creates a stronger competitor to DSM-Firmenich and Givaudan in the specialty ingredients space. Suppliers of natural flavors and starths, such as Sensient Technologies (SXT), may face intensified pricing pressure. Conversely, agricultural firms supplying non-GMO and organic raw materials could see increased demand from the enlarged Ingredion.
A key risk involves the execution of the integration across different corporate cultures and operational footprints. Any delays in achieving projected synergies could pressure Ingredion's margin profile and stock valuation. Investor focus will shift to the company's ability to cross-sell Tate & Lyle's sucralose portfolio with its own stevia-based solutions.
Institutional flow data indicates mixed positioning, with some long-only funds adding to INGR positions while certain hedge funds have initiated pairs trades, shorting more commodity-exposed peers like Archer-Daniels-Midland (ADM). The deal underscores a sector-wide imperative to move up the value chain, potentially triggering further consolidation among mid-cap ingredient providers.
Regulatory approval is the primary near-term catalyst, with a decision from the European Commission's competition directorate expected by Q4 2026. Investors should monitor Ingredion's Q2 2026 earnings call on July 29, 2026, for updated overlap guidance and integration plans. The closing of the transaction is anticipated before the end of 2026.
Key technical levels for INGR stock include near-term support at the 50-day moving average of $115.50 and resistance around the 52-week high of $122.75. A successful breach of the $125 level on high volume would signal strong market endorsement of the strategic rationale.
The combined company's first major test will be its Q1 2027 earnings report, which will provide the initial read on post-merger financial performance. Market participants will scrutinize margin trends in the legacy Ingredion business to ensure the core operations remain stable during the integration phase.
Ingredion has maintained a consistent dividend for over two decades. The company has stated its commitment to the current dividend policy, though the increased debt load from the acquisition may slow the pace of future dividend growth in the near term. The board will likely prioritize debt reduction to an EBITDA ratio below 2.5x before considering significant dividend hikes.
Ingredion gains Tate & Lyle's specialty sweeteners, including Splenda sucralose, and a broad portfolio of texturants, stabilizers, and oat-based ingredients. These products are used in beverages, dairy, and baked goods to reduce sugar, improve texture, and add fiber. The acquisition significantly bolsters Ingredion's offerings in the rapidly growing health and wellness segment.
The 2021 merger of DuPont's Nutrition & Biosciences unit with IFF was a larger-scale transaction valued at over $26 billion, creating a definitive market leader. Ingredion's acquisition is more focused, aiming to establish a clear number-two position in specific niches like specialty sweeteners rather than achieving breadth across all food science categories. The strategic goal is competitive scale, not market dominance.
The acquisition strategically repositions Ingredion as a leading integrated provider of specialty food ingredients.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.
Vortex HFT is our free MT4/MT5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. Trades 24/5.
Trade 800+ global stocks & ETFs
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.